Multiple endocrine neoplasia type 2 prevention: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
==Secondary Prevention== | ==Secondary Prevention== | ||
{| style="border: 2px solid #DCDCDC; font-size: 90%; width: 60%;" align=left | |||
! style="padding: 0 5px; font-size: 120%; background: #4479BA" align=left| ''{{fontcolor|#FFF| Surveillance of multiple endocrine neoplasia type 2}}'' | |||
|- | |||
! style="padding: 0 5px; font-size: 95%; background: #DCDCDC" align=left| '''Serum calium level annually for people diagnosed with multiple endocrine neoplasia type 2A )''' | |||
|- | |||
! style="padding: 0 5px; font-size: 95%; background: #DCDCDC" align=left | '''Recurrent or residual medullary thyroid cancer post thyroidectomy is detected by measurement of serum calcitonin annually''' | |||
|- | |||
! style="padding: 0 5px; font-size: 95%; background: #DCDCDC" align=left | '''[[Catacholamine]]s, [[epinephrine]] and [[norepinephrine]] yearly for MEN 2A and MEN 2B patients to detect pheochromocytoma''' | |||
|- | |||
! style="padding: 0 5px; font-size: 95%; background: #DCDCDC" align=left | '''[[Magnetic resonance imaging]] and [[computerized tomography]] for [[pheochromocytoma]] every 2-4 years''' | |||
|- | |||
! style="padding: 0 5px; font-size: 95%; background: #DCDCDC" align=left | '''[[Parathyroid hormone]] level yearly for MEN 2A to detect hypoparathyroidism''' | |||
|} | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} |
Revision as of 18:51, 28 September 2015
Multiple endocrine neoplasia type 2 Microchapters |
Differentiating Multiple endocrine neoplasia type 2 from other Diseases |
---|
Diagnosis |
Treatment |
Multiple endocrine neoplasia type 2 prevention On the Web |
American Roentgen Ray Society Images of Multiple endocrine neoplasia type 2 prevention |
Directions to Hospitals Treating Multiple endocrine neoplasia type 2 |
Risk calculators and risk factors for Multiple endocrine neoplasia type 2 prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Overview
Secondary Prevention
Surveillance of multiple endocrine neoplasia type 2 |
---|
Serum calium level annually for people diagnosed with multiple endocrine neoplasia type 2A ) |
Recurrent or residual medullary thyroid cancer post thyroidectomy is detected by measurement of serum calcitonin annually |
Catacholamines, epinephrine and norepinephrine yearly for MEN 2A and MEN 2B patients to detect pheochromocytoma |
Magnetic resonance imaging and computerized tomography for pheochromocytoma every 2-4 years |
Parathyroid hormone level yearly for MEN 2A to detect hypoparathyroidism |